U.S. markets close in 5 hours 44 minutes
  • S&P 500

    3,894.95
    -36.38 (-0.93%)
     
  • Dow 30

    31,365.38
    -247.64 (-0.78%)
     
  • Nasdaq

    13,775.52
    -189.97 (-1.36%)
     
  • Russell 2000

    2,235.60
    -20.51 (-0.91%)
     
  • Crude Oil

    60.99
    -0.15 (-0.25%)
     
  • Gold

    1,771.80
    -1.00 (-0.06%)
     
  • Silver

    27.07
    -0.25 (-0.90%)
     
  • EUR/USD

    1.2071
    +0.0025 (+0.21%)
     
  • 10-Yr Bond

    1.3130
    +0.0120 (+0.92%)
     
  • GBP/USD

    1.3946
    +0.0083 (+0.60%)
     
  • USD/JPY

    105.8600
    -0.0110 (-0.01%)
     
  • BTC-USD

    51,990.73
    +920.36 (+1.80%)
     
  • CMC Crypto 200

    1,061.34
    +1.57 (+0.15%)
     
  • FTSE 100

    6,623.59
    -87.31 (-1.30%)
     
  • Nikkei 225

    30,236.09
    -56.10 (-0.19%)
     

Veru Raises $100M Via Equity At 10% Discount

  • Oops!
    Something went wrong.
    Please try again later.
Vandana Singh
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Veru Inc (NASDAQ: VERUpriced its underwritten public offering of 6.5 million shares at $15.50 per share, with gross proceeds of approximately $100 million. Underwriters have an option to purchase up to an additional 967,741 shares.

  • The offer price represents a discount of 10% from the last close price of $17.21 on Wednesday.

  • Jefferies is acting as the sole book-running manager for the offering, expected to close by February 22.

  • Veru plans to use the net proceeds for R&D activities, clinical trials, regulatory and sales and marketing expenditures, working capital, and other general corporate purposes.

  • Earlier this month, Veru reported positive efficacy and safety results from a Phase 2 trial evaluating VERU-111 versus placebo in hospitalized patients at high risk for Acute Respiratory Distress Syndrome from SARS-CoV-2.

  • In December, the company announced data from Phase 2 study of recently in-licensed enobosarm in AR+/ER+/HER2- metastatic breast cancer and who have developed resistance to estrogen receptor-targeted endocrine therapies and chemotherapy. Enobosarm demonstrated a clinically meaningful six-month clinical benefit rate of 35.3% and had a good safety profile with no reports of virilization, increased hematocrit, or liver toxicity.

  • Price Action: VERU shares are trading lower by 6.2% at $16.15 in the premarket session on the last check Thursday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.